MariTide

Synonyms: MARITIDE; GLP-1/Glucagon receptor agonist; dual incretin agonist

MariTide is a synthetic peptide dual agonist designed to activate both the glucagon-like peptide-1 (GLP-1) and glucagon receptors.

This investigational compound is being developed for the treatment of metabolic disorders, including obesity and type 2 diabetes.

Its dual mechanism of action aims to enhance glucose-dependent insulin secretion while promoting energy expenditure through glucagon receptor activation, offering a promising approach to weight management and glycemic control.

Chemical Structure & Properties

MariTide is a synthetic peptide with a molecular structure that includes a fatty acid moiety for prolonged half-life, similar to other incretin-based therapies. The peptide is composed of amino acids that confer resistance to enzymatic degradation, enhancing its in vivo stability. Its exact sequence and modifications are proprietary, but the compound is supplied as a lyophilized powder with high purity.

Supply & Documentation

• Capacity: Available in research quantities; bulk production on request.
• Lieferzeit: 5-10 business days for standard orders.
• Dokumentation: COA, MSDS, TDS provided with each shipment.
• Verpackung: Sealed vials, 5 g, 10 g, 50 g, or custom packing.

Angebotsanfrage

• Unsere Adresse: 280 Main Street, Xi’an, Shaanxi, China
• LyvBio GmbH. — E-Mail: info@lyvbio.com